Peringatan Keamanan

hepatoxicity

Dactinomycin

DB00970

small molecule approved investigational

Deskripsi

A compound composed of a two cyclic peptides attached to a phenoxazine that is derived from streptomyces parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)

Struktur Molekul 2D

Berat 1255.417
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 36 hours
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

poorly absorbed from gastrointestinal tract

Metabolisme

hepatic

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

775 Data
Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Dactinomycin.
Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with Dactinomycin.
Peginterferon alfa-2a The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Dactinomycin.
Interferon alfa-n1 The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Dactinomycin.
Interferon alfa-n3 The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Dactinomycin.
Peginterferon alfa-2b The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Dactinomycin.
Anakinra The risk or severity of adverse effects can be increased when Anakinra is combined with Dactinomycin.
Interferon gamma-1b The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Dactinomycin.
Interferon alfa-2a The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Dactinomycin.
Aldesleukin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Dactinomycin.
Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Dactinomycin.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dactinomycin.
Pegaspargase The risk or severity of adverse effects can be increased when Pegaspargase is combined with Dactinomycin.
Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Dactinomycin.
Interferon beta-1b The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Dactinomycin.
Interferon alfacon-1 The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Dactinomycin.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Dactinomycin.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Dactinomycin.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Dactinomycin.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dactinomycin.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Dactinomycin.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dactinomycin.
Alefacept The risk or severity of adverse effects can be increased when Alefacept is combined with Dactinomycin.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Dactinomycin.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Dactinomycin.
Interferon alfa-2b The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Dactinomycin.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Dactinomycin.
Phenylalanine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Dactinomycin.
Flunisolide The risk or severity of adverse effects can be increased when Flunisolide is combined with Dactinomycin.
Bortezomib The risk or severity of adverse effects can be increased when Bortezomib is combined with Dactinomycin.
Cladribine Dactinomycin may increase the immunosuppressive activities of Cladribine.
Carmustine The risk or severity of adverse effects can be increased when Carmustine is combined with Dactinomycin.
Amsacrine The risk or severity of adverse effects can be increased when Amsacrine is combined with Dactinomycin.
Bleomycin The risk or severity of adverse effects can be increased when Bleomycin is combined with Dactinomycin.
Chlorambucil The risk or severity of adverse effects can be increased when Chlorambucil is combined with Dactinomycin.
Raltitrexed The risk or severity of adverse effects can be increased when Raltitrexed is combined with Dactinomycin.
Mitomycin The risk or severity of adverse effects can be increased when Mitomycin is combined with Dactinomycin.
Bexarotene The risk or severity of adverse effects can be increased when Bexarotene is combined with Dactinomycin.
Vindesine The risk or severity of adverse effects can be increased when Vindesine is combined with Dactinomycin.
Floxuridine The risk or severity of adverse effects can be increased when Floxuridine is combined with Dactinomycin.
Indomethacin The risk or severity of adverse effects can be increased when Indomethacin is combined with Dactinomycin.
Tioguanine The risk or severity of adverse effects can be increased when Tioguanine is combined with Dactinomycin.
Vinorelbine The risk or severity of adverse effects can be increased when Vinorelbine is combined with Dactinomycin.
Dexrazoxane The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Dactinomycin.
Beclomethasone dipropionate The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Dactinomycin.
Streptozocin The risk or severity of adverse effects can be increased when Streptozocin is combined with Dactinomycin.
Trifluridine The risk or severity of adverse effects can be increased when Trifluridine is combined with Dactinomycin.
Gemcitabine The risk or severity of adverse effects can be increased when Gemcitabine is combined with Dactinomycin.
Betamethasone The risk or severity of adverse effects can be increased when Betamethasone is combined with Dactinomycin.
Teniposide The risk or severity of adverse effects can be increased when Teniposide is combined with Dactinomycin.
Epirubicin The risk or severity of adverse effects can be increased when Epirubicin is combined with Dactinomycin.
Chloramphenicol The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Dactinomycin.
Lenalidomide The risk or severity of adverse effects can be increased when Lenalidomide is combined with Dactinomycin.
Altretamine The risk or severity of adverse effects can be increased when Altretamine is combined with Dactinomycin.
Zidovudine The risk or severity of adverse effects can be increased when Zidovudine is combined with Dactinomycin.
Cisplatin The risk or severity of adverse effects can be increased when Cisplatin is combined with Dactinomycin.
Oxaliplatin The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Dactinomycin.
Cyclophosphamide The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Dactinomycin.
Fluorouracil The risk or severity of adverse effects can be increased when Fluorouracil is combined with Dactinomycin.
Propylthiouracil The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Dactinomycin.
Pentostatin The risk or severity of adverse effects can be increased when Pentostatin is combined with Dactinomycin.
Methotrexate The risk or severity of adverse effects can be increased when Methotrexate is combined with Dactinomycin.
Vinblastine The risk or severity of adverse effects can be increased when Vinblastine is combined with Dactinomycin.
Fluticasone propionate The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Dactinomycin.
Fluocinolone acetonide The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Dactinomycin.
Linezolid The risk or severity of adverse effects can be increased when Linezolid is combined with Dactinomycin.
Imatinib The risk or severity of adverse effects can be increased when Imatinib is combined with Dactinomycin.
Triamcinolone The risk or severity of adverse effects can be increased when Triamcinolone is combined with Dactinomycin.
Clofarabine The risk or severity of adverse effects can be increased when Clofarabine is combined with Dactinomycin.
Prednisone The risk or severity of adverse effects can be increased when Prednisone is combined with Dactinomycin.
Pemetrexed The risk or severity of adverse effects can be increased when Pemetrexed is combined with Dactinomycin.
Fludrocortisone The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Dactinomycin.
Mycophenolate mofetil The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Dactinomycin.
Daunorubicin The risk or severity of adverse effects can be increased when Daunorubicin is combined with Dactinomycin.
Irinotecan The risk or severity of adverse effects can be increased when Irinotecan is combined with Dactinomycin.
Methimazole The risk or severity of adverse effects can be increased when Methimazole is combined with Dactinomycin.
Etoposide The risk or severity of adverse effects can be increased when Etoposide is combined with Dactinomycin.
Sulfasalazine The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Dactinomycin.
Dacarbazine The risk or severity of adverse effects can be increased when Dacarbazine is combined with Dactinomycin.
Temozolomide The risk or severity of adverse effects can be increased when Temozolomide is combined with Dactinomycin.
Penicillamine The risk or severity of adverse effects can be increased when Penicillamine is combined with Dactinomycin.
Prednisolone The risk or severity of adverse effects can be increased when Prednisolone is combined with Dactinomycin.
Mechlorethamine The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Dactinomycin.
Azacitidine The risk or severity of adverse effects can be increased when Azacitidine is combined with Dactinomycin.
Carboplatin The risk or severity of adverse effects can be increased when Carboplatin is combined with Dactinomycin.
Methylprednisolone The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Dactinomycin.
Cytarabine The risk or severity of adverse effects can be increased when Dactinomycin is combined with Cytarabine.
Azathioprine The risk or severity of adverse effects can be increased when Dactinomycin is combined with Azathioprine.
Hydroxyurea The risk or severity of adverse effects can be increased when Dactinomycin is combined with Hydroxyurea.
Busulfan The risk or severity of adverse effects can be increased when Dactinomycin is combined with Busulfan.
Mycophenolic acid The risk or severity of adverse effects can be increased when Dactinomycin is combined with Mycophenolic acid.
Mercaptopurine The risk or severity of adverse effects can be increased when Dactinomycin is combined with Mercaptopurine.
Thalidomide The risk or severity of adverse effects can be increased when Dactinomycin is combined with Thalidomide.
Melphalan The risk or severity of adverse effects can be increased when Dactinomycin is combined with Melphalan.
Fludarabine The risk or severity of adverse effects can be increased when Dactinomycin is combined with Fludarabine.
Flucytosine The risk or severity of adverse effects can be increased when Dactinomycin is combined with Flucytosine.
Capecitabine The risk or severity of adverse effects can be increased when Dactinomycin is combined with Capecitabine.
Trilostane The risk or severity of adverse effects can be increased when Dactinomycin is combined with Trilostane.
Procarbazine The risk or severity of adverse effects can be increased when Dactinomycin is combined with Procarbazine.
Idarubicin The risk or severity of adverse effects can be increased when Dactinomycin is combined with Idarubicin.

Target Protein

DNA
DNA topoisomerase 2 TOP2A
DNA topoisomerase 1 TOP1

Referensi & Sumber

Synthesis reference: Waksman, S.A. and Woodruff, H.B.; US. Patent 2,378,876; June 19,1945; assigned to Merck & Co., Inc.
Artikel (PubMed)
  • PMID: 2410919
    Sobell HM: Actinomycin and DNA transcription. Proc Natl Acad Sci U S A. 1985 Aug;82(16):5328-31.
  • PMID: 16803542
    Turan T, Karacay O, Tulunay G, Boran N, Koc S, Bozok S, Kose MF: Results with EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) chemotherapy in gestational trophoblastic neoplasia. Int J Gynecol Cancer. 2006 May-Jun;16(3):1432-8.
  • PMID: 17102824
    Abd El-Aal HH, Habib EE, Mishrif MM: Wilms' tumor: the experience of the pediatric unit of Kasr El-Aini center of radiation oncology and nuclear medicine (NEMROCK). J Egypt Natl Canc Inst. 2005 Dec;17(4):308-14.
  • PMID: 15543019
    Khatua S, Nair CN, Ghosh K: Immune-mediated thrombocytopenia following dactinomycin therapy in a child with alveolar rhabdomyosarcoma: the unresolved issues. J Pediatr Hematol Oncol. 2004 Nov;26(11):777-9.

Contoh Produk & Brand

Produk: 13 • International brands: 1
Produk
  • Cosmegen
    Injection, powder, lyophilized, for solution • 0.5 mg/1mL • Intravenous • US • Approved
  • Cosmegen
    Injection, powder, lyophilized, for solution • 0.5 mg/1mL • Intravenous • US • Approved
  • Cosmegen
    Injection, powder, lyophilized, for solution • 0.5 mg/1mL • Intravenous • US • Approved
  • Cosmegen
    Powder, for solution • 0.5 mg / vial • Intravenous • Canada • Approved
  • Dactinomycin
    Injection, powder, for solution • 500 ug/1 • Intravenous • US • Generic • Approved
  • Dactinomycin
    Injection, powder, lyophilized, for solution • 0.5 mg/1mL • Intravenous • US • Generic • Approved
  • Dactinomycin
    Injection, powder, lyophilized, for solution • 0.5 mg/1mL • Intravenous • US • Generic • Approved
  • Dactinomycin
    Injection, powder, lyophilized, for solution • 0.5 mg/1mL • Intravenous • US • Generic • Approved
Menampilkan 8 dari 13 produk.
International Brands
  • Lyovac Cosmegen — Lundbeck

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul